- Aditxt (NASDAQ:ADTX) to acquire a company focused on developing Point-of-Care diagnostics for early detection of diseases including cancers and SARS-CoV-2 through a range of non-invasive and affordable point of care and at-home/in-office test kits.
The target holds an exclusive license in U.S. & Canada for at-home and in-office rapid antigen COVID-19 test.
EUA application for the COVID-19 rapid antigen test was submitted in September 2021.
- “The potential acquisition is complementary to AditxtScore technologically and commercially, and is one of the main components to executing our growth plans in 2022. We believe that Point-of-Care rapid testing combined with our current capabilities is key to driving the transformation from reactive care to precision-driven, proactive care delivery.” said Amro Albanna, Co-Founder and CEO.